Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA1 | P00915 | 3/20 | 0.36 |
| ▸ | CA2 | P00918 | 3/20 | 0.36 |
| ▸ | EPHX1 | P07099 | 4/20 | 0.35 |
| ▸ | CA12 | O43570 | 2/20 | 0.34 |
| ▸ | CA9 | Q16790 | 2/20 | 0.34 |
| ▸ | CES2 | O00748 | 1/20 | 0.32 |
| ▸ | CES1 | P23141 | 1/20 | 0.32 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.31 |
| ▸ | ACHE | P22303 | 1/20 | 0.31 |
| ▸ | NAAA | Q02083 | 1/20 | 0.31 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8435994 | 0.97 | — | — | |
| Biphenyl SCHEMBL11430652 | 0.93 | ALDH1A1 (0.36) | CA1CA2EPHX1CA12CA9 | |
| SCHEMBL15941586 | 0.92 | — | — | |
| SCHEMBL4453884 | 0.86 | — | — | |
| SCHEMBL3086400 | 0.79 | CA1 (0.34) | CA1CA2EPHX1CA12CA9 | |
| SCHEMBL673199 | 0.78 | CA1 (0.39) | CA1CA2EPHX1CA12CA9 | |
| SCHEMBL3066085 | 0.76 | CA1 (0.37) | CA1CA2EPHX1CA12CA9 | |
| SCHEMBL28946904 | 0.75 | — | — | |
| SCHEMBL29001743 | 0.75 | — | — | |
| SCHEMBL29182420 | 0.75 | TSHR (0.31) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 36 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250346898-A1 | Linkage Modified Oligomeric Compounds and Uses Thereof | IONIS PHARMACEUTICALS, INC. (US) | 2025-11-13 | — | — | US | disclosed |
| EP-4532724-A1 | LINKAGE MODIFIED OLIGOMERIC COMPOUNDS AND USES THEREOF | Ionis Pharmaceuticals, Inc. (US) | 2025-04-09 | — | — | EP | disclosed |
| WO-2023235817-A1 | LINKAGE MODIFIED OLIGOMERIC COMPOUNDS AND USES THEREOF | IONIS PHARMACEUTICALS, INC. (US) | 2023-12-07 | — | — | WO | disclosed |
| EP-4116310-A1 | METHOD FOR MANUFACTURING PHOSPHONATE ESTERS AND METHOD FOR MANUFACTURING PHOSPHATE ESTERS | FUJIFILM Wako Pure Chemical Corporation (JP) | 2023-01-11 | — | — | EP | disclosed |
| US-10479809-B2 | Method for producing alkenyl phosphorus compound | MARUZEN PETROCHEMICAL CO., LTD. (JP) | 2019-11-19 | — | — | US | disclosed |
| CN-106165175-B | High molecular electrolyte composition and polyelectrolyte membrane, film electrode composite element and the polymer electrolyte fuel cell for using it | 东丽株式会社 | 2019-11-08 | — | — | CN | disclosed |
| US-20190263847-A1 | METHOD FOR PRODUCING ALKENYL PHOSPHORUS COMPOUND | MARUZEN PETROCHEMICAL CO., LTD. (JP) | 2019-08-29 | — | — | US | disclosed |
| EP-3348561-A1 | METHOD FOR PRODUCING ALKENYL PHOSPHORUS COMPOUND | Maruzen Petrochemical Co., Ltd. (JP) | 2018-07-18 | — | — | EP | disclosed |
| US-9920083-B2 | Image recording paper medium and image recording method | FUJIFILM CORPORATION (JP) | 2018-03-20 | — | — | US | disclosed |
| EP-2960691-B1 | NEAR-INFRARED ABSORBING COMPOSITION, NEAR-INFRARED BLOCKING FILTER, METHOD FOR PRODUCING NEAR-INFRARED BLOCKING FILTER, CAMERA MODULE AND METHOD FOR MANUFACTURING CAMERA MODULE | FUJIFILM CORP (JP) | 2017-09-27 | — | — | EP | disclosed |
| US-20070010489-A1 | Cellular accumulation of phosphonate analogs of hiv protease inhibitor compounds | GILEAD SCIENCES, INC. | 2007-01-11 | — | — | US | disclosed |
| EP-1711617-A1 | METHOD AND COMPOSITIONS FOR IDENTIFYING ANTI-HIV THERAPEUTICS COMPOUNDS | GILEAD SCIENCES, INC. (US) | 2006-10-18 | — | — | EP | disclosed |
| WO-2005064008-A9 | METHOD AND COMPOSITIONS FOR IDENTIFYING ANTI-HIV THERAPEUTIC COMPOUNDS | GILEAD SCIENCES INC (US) | 2006-09-28 | — | — | WO | disclosed |
| US-20050239054-A1 | Method and compositions for identifying anti-HIV therapeutic compounds | GILEAD SCIENCES. INC. | 2005-10-27 | — | — | US | disclosed |
| US-20050209197-A1 | Cellular accumulation of phosphonate analogs of HIV protease inhibitor compounds | GILEAD SCIENCES, INC. | 2005-09-22 | — | — | US | disclosed |
| WO-2005064008-A1 | METHOD AND COMPOSITIONS FOR IDENTIFYING ANTI-HIV THERAPEUTIC COMPOUNDS | GILEAD SCIENCES, INC. (US) | 2005-07-14 | — | — | WO | disclosed |
| EP-1509537-A2 | CELLULAR ACCUMULATION OF PHOSPHONATE ANALOGS OF HIV PROTEASE INHIBITOR COMPOUNDS AND THE COMPOUNDS AS SUCH | GILEAD SCIENCES, INC. (US) | 2005-03-02 | — | — | EP | disclosed |
| WO-2003090690-A2 | CELLULAR ACCUMULATION OF PHOSPHONATE ANALOGS OF HIV PROTEASE INHIBITOR COMPOUNDS AND THE COMPOUNDS AS SUCH | GILEAD SCIENCES, INC. (US) | 2003-11-06 | — | — | WO | disclosed |
| US-5922654-A | TWO OR MORE ORGANOMETALLIC COMPOUNDS WHERE THE METAL IS A TRANSITION METAL OR SEMIMETAL, OR ZINC; FOR EXAMPLE, ZINC DIALKYLDITHIOPHOSPHATE, OR NICKEL DIALKYLDITHIOCARBAMATE; HIGHER LOAD BEARING PROPERTIES, HIGH TEMPERATURE PERFORMANCE | NSK LTD. (JP) | 1999-07-13 | — | — | US | disclosed |
| US-4028306-A | COATINGS | BAYER AKTIENGESELLSCHAFT (DT) | 1977-06-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050209197-A1 | Cellular accumulation of phosphonate analogs of HIV protease inhibitor compounds | PPA1, PPME1, PNP | CA1 3711/4885CA2 3935/4885EPHX1 3093/4885 |
| US-20050239054-A1 | Method and compositions for identifying anti-HIV therapeutic compounds | CES1, PNP, PGLS | CA1 3093/4885CA2 3487/4885EPHX1 297/4885 |
| US-10479809-B2 | Method for producing alkenyl phosphorus compound | ORC3, OR10J3, ORAI3 | CA1 679/4885CA2 269/4885EPHX1 1996/4885 |
| US-20070010489-A1 | Cellular accumulation of phosphonate analogs of hiv protease inhibitor compounds | PPA1, PNP, PPME1 | CA1 3725/4885CA2 3915/4885EPHX1 3164/4885 |
| US-20190263847-A1 | METHOD FOR PRODUCING ALKENYL PHOSPHORUS COMPOUND | ORC3, OR10J3, ALK | CA1 686/4885CA2 177/4885EPHX1 1436/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.